CYP2D6 genetic polymorphisms impact on tamsulosin efficacy and safety in patients with benign prostatic hyperplasia
The present study identified potential markers that could serve as predictors of the effectiveness of tamsulosin. Specifically, genetic markers such as <i>CYP2D6*4</i>, <i>CYP2D6*10</i>, <i>CYP2D6*41</i>, and non-genetic factors like BMI and prostate volume were associated with the clinical efficacy of tamsulosin therapy in LUTS/BPH patients..
Authors
- Sh. P. Abdullaev (ORCID: https://orcid.org/0000-0001-9001-1499)
- Тучкова Светлана Николаевна (ORCID: https://orcid.org/0009-0001-2744-2752)
- М Н Шатохин (ORCID: https://orcid.org/0000-0002-1285-7357)
- Sh. P. Abdullaev
- П. О. Бочков (ORCID: https://orcid.org/0000-0001-8555-5969)
- О Б Лоран (ORCID: https://orcid.org/0000-0002-7531-1511)
- A V Krasnov
- О В Теодорович
- I. V. Sychev (ORCID: https://orcid.org/0000-0003-0227-2651)
- Dmitry Alekseevich Sychev (ORCID: https://orcid.org/0000-0002-4496-3680)
Institutions
- Russian Railways (RU)
- Kurchatov Institute (RU)
- National Research Mordovia State University (RU)
- Russian Medical Academy of Continuous Professional Education (RU)
Publication Details
- Journal
- Drug Metabolism and Personalized Therapy
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1515/dmpt-2024-0061
- Citations
- 1
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 1.84